Halozyme Switzerland ^Company

Halozyme Switzerland GmbH is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. The company's proprietary program, investigational drug PEGPH20 applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models.